Showing results (1801-1810 of 2,473) with videos related to
Sort By:
Pageof 248
Cancer Treatment Reviews|July 20, 2023
Uveal melanoma: In the era of new treatmentsM Wespiser, E Neidhardt, S NegrierCancer Treatment Reviews|July 12, 2023
The immunogram of inflammatory breast cancerCarmine Valenza, Dario Trapani, Nicola Fusco, et al.Cancer Treatment Reviews|July 1, 2023
Managing cisplatin-ineligible patients with resected, high-risk, locally advanced squamous cell carcinoma of the head and neck: Is there a standard of care?Robert I Haddad, Kevin Harrington, Makoto Tahara, et al.Cancer Treatment Reviews|August 14, 2023
Expert consensus guidelines for the prophylaxis and management of tumor lysis syndrome in the United States: Results of a modified Delphi panelAnthony J Perissinotti, Michael R Bishop, Joseph Bubalo, et al.Cancer Treatment Reviews|August 14, 2023
Shaping the tumor immune microenvironment of SCLC: Mechanisms, and opportunities for immunotherapyYunfei Chen, Hui Li, Yun FanCancer Treatment Reviews|September 1, 2023
The role of radiation therapy in the management of primary retroperitoneal sarcoma: A systematic review and clinical practice guidelines from the Australia and New Zealand Sarcoma AssociationAnna Lawless, Deborah Di-Xin Zhou, Joshua McDonough, et al.Cancer Treatment Reviews|August 28, 2023
Tucatinib's journey from clinical development to clinical practice: New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spreadCarmen Criscitiello, Chiara Corti, Michelino De Laurentiis, et al.Cancer Treatment Reviews|September 28, 2023
Regulatory T cells in gastric cancer: Key controllers from pathogenesis to therapyIon Negura, Mariana Pavel-Tanasa, Mihai DanciuCancer Treatment Reviews|September 26, 2023
Estrogen deprivation effects of endocrine therapy in breast cancer patients: Incidence, management and outcomeLinda Cucciniello, Giovanna Garufi, Rossana Di Rienzo, et al.Cancer Treatment Reviews|September 22, 2023
A systematic review of recent phase-II trials in refractory or recurrent osteosarcoma: Can we inform future trial design?Roelof van Ewijk, Morgane Cleirec, Nikolas Herold, et al.Pageof 248